: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, March 2026
Free Subscription

Abstracts
Retrieve all available abstracts of the following 325 articles:
HTML format

Single Articles

WALLERSON J, Rostampour S, Teng S, Kidane D, et al
Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment.
J Cell Mol Med. 2026;30:e71064.
PubMed
Abstract available

MELLEMA JJ, Stockem CF, Herberts C, Cheung SK, et al
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2026 Feb 27. doi: 10.1038/s41591-026-04271.
PubMed
Abstract available

SHENG Y, Fan L, Zhu S, Wang Y, et al
Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectomy.
Urol Oncol. 2026;44:111039.
PubMed
Abstract available

DENG Z, Yan Z, Chen Z
Post-translational modifications: Principal regulators of bladder cancer.
Mol Biol Rep. 2026;53:446.
PubMed

LI Y, Ma Y, Lai J, Wan Q, et al
Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations.
Discov Oncol. 2026 Feb 27. doi: 10.1007/s12672-025-04114.
PubMed

BENIJTS R, Akand M, Tipirdamaz M, Mennes J, et al
External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.
Minerva Urol Nephrol. 2026 Feb 27. doi: 10.23736/S2724-6051.25.06600.
PubMed
Abstract available

YING X, Huang Y, Huang J, Cai Q, et al
m(5)C-Modified tRF3b-Cys(GCA)-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.
Adv Sci (Weinh). 2026 Feb 27:e22294. doi: 10.1002/advs.202522294.
PubMed
Abstract available

MATSUO T, Mori S, Honda H, Kakita S, et al
Preoperative Gamma-Glutamyltransferase-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
Medicina (Kaunas). 2026;62:343.
PubMed
Abstract available

PEREIRA M, Vale N
Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.
Genes (Basel). 2026;17:184.
PubMed
Abstract available

SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction.
Genes (Basel). 2026;17:153.
PubMed
Abstract available

CAN VG
Molecular Characterization of Muscle-Invasive Bladder Cancer: Key MicroRNAs, Transcription Factors, and Differentially Expressed Genes.
Genes (Basel). 2026;17:122.
PubMed
Abstract available

OZYURT N, Turhan A
Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.
Diagnostics (Basel). 2026;16:574.
PubMed
Abstract available

PARADA D, Onoiu AI, Iftimie S, Camps J, et al
A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer.
Antioxidants (Basel). 2026;15:198.
PubMed
Abstract available

BEKESCHUS S, Berner J, Edelmann J, Wolff CM, et al
Synergistic Toxicity of Cold Gas Plasma and Cisplatin in Bladder Cancer Cells.
Cancers (Basel). 2026;18:675.
PubMed
Abstract available

GRIER AL, Zhong JY, Basourakos S, Calaway A, et al
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2026;18:623.
PubMed
Abstract available

RIBEIRO E, Vale N
Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.
Cancers (Basel). 2026;18:562.
PubMed
Abstract available

ZENG S, Xu Z, Xing S, Zhang Y, et al
Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion.
Eur J Med Res. 2026 Feb 26. doi: 10.1186/s40001-026-04029.
PubMed
Abstract available

BAEK SW, Byun YJ, Piao XM, Seo JW, et al
Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy.
BMC Med. 2026 Feb 27. doi: 10.1186/s12916-026-04745.
PubMed
Abstract available

HUANG GK, Zhang XX, Huang LY, Un HC, et al
Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.
J Transl Med. 2026 Feb 26. doi: 10.1186/s12967-026-07924.
PubMed
Abstract available

REN S, Dai R, Zheng Z, Liu Q, et al
Corrigendum to "A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer" [Nanomed Nanotechnol Biol Med 49 (April 2023) 102661].
Nanomedicine. 2026 Feb 25:102916. doi: 10.1016/j.nano.2026.102916.
PubMed

SCHMID SC, Jahnen M, Schiller K, Sauter A, et al
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
Eur Urol Oncol. 2026 Feb 25:S2588-9311(26)00056.
PubMed
Abstract available

TRAN MA, Cho BA, Izadmehr S, Yoo SK, et al
A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
Cancer Discov. 2026 Feb 27. doi: 10.1158/2159-8290.CD-25-1774.
PubMed
Abstract available

KATONGTUNG P, Shiangjen K, Cholamjiak W, Naravejsakul K, et al
MRI-Based Bladder Cancer Staging via YOLOv11 Segmentation and Deep Learning Classification.
Diseases. 2026;14:45.
PubMed
Abstract available

PAVALEAN MI, Lambrescu IM, Gaina G, Madan VL, et al
CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.
Diseases. 2026;14:44.
PubMed
Abstract available

BUONERBA C, Baio R, Crocetto F, Bruzzese D, et al
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.
Curr Oncol. 2026;33:128.
PubMed
Abstract available

ZHANG X, Su S, Liu L, Song F, et al
Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.
Front Oncol. 2026;16:1724968.
PubMed
Abstract available

NIU S, Li L, Jia W, Feng H, et al
Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.
FEBS Open Bio. 2026 Feb 25. doi: 10.1002/2211-5463.70221.
PubMed
Abstract available

HABICHER M, Swoboda C, Hauptmann A, Koch C, et al
Enhanced recovery after radical cystectomy for bladder cancer: a prospective observational case -control study.
BMC Urol. 2026 Feb 25. doi: 10.1186/s12894-026-02093.
PubMed

LEE TJ, Qiu L, Long J, Mach KE, et al
CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.
Sci Data. 2026 Feb 26. doi: 10.1038/s41597-026-06887.
PubMed
Abstract available

TAKEUCHI M, Tamada T
Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.
Magn Reson Med Sci. 2026 Feb 26. doi: 10.2463/mrms.rev.2025-0213.
PubMed
Abstract available

GUERRERO-RAMOS F
BCG and Systemic Immunotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Lights and Shadows.
Actas Urol Esp (Engl Ed). 2026 Feb 23:501936. doi: 10.1016/j.acuroe.2026.501936.
PubMed

WEI X, Cai L, Li N, Fang Y, et al
High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics.
Biosens Bioelectron. 2026;302:118545.
PubMed
Abstract available

TRATNJEK L, Janev A, Kuret T, Jerman UD, et al
The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.
Front Immunol. 2026;17:1731784.
PubMed
Abstract available

WANG Y, Wu N, Zhang S
Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.
Mol Cancer. 2026 Feb 24. doi: 10.1186/s12943-026-02608.
PubMed

ADIB E, Nassar AH, Alaiwi SA, Baca SC, et al
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.
Mol Cancer Res. 2026 Feb 24. doi: 10.1158/1541-7786.MCR-25-1385.
PubMed
Abstract available

GOEL V, Jain A, Basu D, Patnaik N, et al
Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.
Gulf J Oncolog. 2025;1:60-66.
PubMed
Abstract available

SHAN M, Wang X, Wang Z, Xu C, et al
NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.
Bioact Mater. 2026;61:229-242.
PubMed
Abstract available

HONG X, Wang G, Hong T, Liu X, et al
Glycolysis-related genes for bladder cancer: A Mendelian randomization analysis.
Biochem Biophys Rep. 2026;45:102501.
PubMed
Abstract available

PEYROTTES A, Masson-Lecomte A, Aregui A, Meria P, et al
[Specificities of oncologic surgery in elder patients].
Rev Prat. 2026;76:60-65.
PubMed
Abstract available

ZHANG L, Zhong Y, Yang G, Huang L, et al
Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.
Front Digit Health. 2026;8:1708289.
PubMed
Abstract available

ZHANG L, Gong Y, Chen J, Li M, et al
Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
Front Immunol. 2026;17:1561666.
PubMed
Abstract available

KUCAN BRLIC P, Bellulovich E, Golemac M, Jaksic A, et al
High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread.
Front Immunol. 2026;17:1754848.
PubMed
Abstract available

MUNERA-MARAVILLA E, Perez-Escavy M, Rubio C, Segovia C, et al
Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
J Exp Clin Cancer Res. 2026 Feb 23. doi: 10.1186/s13046-026-03677.
PubMed

CUI J, Chen S, Liu X, Jiang X, et al
PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.
Cell Death Dis. 2026 Feb 23. doi: 10.1038/s41419-026-08498.
PubMed
Abstract available

SEO J, Park JM, Park DJ, Seo I, et al
Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026 Jan 23:102513. doi: 10.1016/j.clgc.2026.102513.
PubMed
Abstract available

XU L, Lin Y, Shi G, Zhang L, et al
Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment.
J Biol Chem. 2026 Feb 20:111304. doi: 10.1016/j.jbc.2026.111304.
PubMed
Abstract available

MISURKA J, Berjaoui MB, Lajkosz K, Cockburn J, et al
PA- versus urologist-performed flexible cystoscopy: A comparative study.
JAAPA. 2026;39:34-36.
PubMed
Abstract available

LUO C, Kuang X, Dai Y, Cai Z, et al
DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
Clin Epigenetics. 2026 Feb 21. doi: 10.1186/s13148-026-02079.
PubMed
Abstract available

XU DM, Chen J, Lin SB, Xu TY, et al
ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
J Transl Med. 2026 Feb 21. doi: 10.1186/s12967-026-07830.
PubMed

CHEN Q, Wu K, Cai B, Yu X, et al
LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
World J Surg Oncol. 2026 Feb 21. doi: 10.1186/s12957-026-04246.
PubMed

FALQUET M, El Ahanidi H, Gomez-Cadena A, Su Z, et al
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.
Nat Commun. 2026 Feb 21. doi: 10.1038/s41467-026-69841.
PubMed
Abstract available

STEMPEL MH, Quezada JP, Belz B, Sun F, et al
Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.
Urol Oncol. 2026 Feb 20:111005. doi: 10.1016/j.urolonc.2026.111005.
PubMed
Abstract available

DI LORENZO G, Di Maio M, Buonerba C
Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
Oncol Ther. 2026 Feb 21. doi: 10.1007/s40487-026-00417.
PubMed
Abstract available

CHEN C, Yang Y, Niu H, Tang Y, et al
Interfacial Electric Locking of the Aptamer Conformation for Accurate Liquid Biopsy Detection.
Nano Lett. 2026;26:2371-2380.
PubMed
Abstract available

SAKTHIVEL DK, Prabhakar P, Iyub MJR, Garje R, et al
Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study.
Clin Genitourin Cancer. 2026;24:102495.
PubMed
Abstract available

TAWAGI K, Khaki AR, Chablani PV, Hoffman-Censits J, et al
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
Clin Genitourin Cancer. 2026;24:102487.
PubMed
Abstract available

SAHIN KC, Simsekoglu MF, Ozden SB, Ercili B, et al
Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights.
Surg Oncol. 2026;64:102344.
PubMed
Abstract available

HUNDEBOLL JH, Olesen AF, Wessel I, Magkos F, et al
Not just about weight: Identifying hidden nutritional vulnerability after radical cystectomy.
Eur J Clin Nutr. 2025 Dec 10. doi: 10.1038/s41430-025-01694.
PubMed
Abstract available

PAN W, Xing J, Chen X, Xue R, et al
Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.
Int J Surg. 2026;112:4762-4788.
PubMed
Abstract available

WENG HW, Ting HK, Wang HH, Peng TJ, et al
Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.
J Transl Med. 2026 Mar 4. doi: 10.1186/s12967-026-07943.
PubMed

ROUPRET M
Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladd
Ann Oncol. 2026 Mar 3:S0923-7534(26)00046-3. doi: 10.1016/j.annonc.2026.
PubMed

ZHOU M, Xue X, Li H, Chen Z, et al
Decoding the metabolic-immune axis for novel therapeutics in bladder cancer.
Biochim Biophys Acta Rev Cancer. 2026 Mar 2:189569.
PubMed
Abstract available

YANG M, Chai X, Ye D, Zhao A, et al
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin immunotherapy.
J Med Econ. 2026;29:672-687.
PubMed
Abstract available

BANG S, Joo SM, Kim DK, Kwon JK, et al
Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences.
Investig Clin Urol. 2026;67:162-169.
PubMed
Abstract available

YANG Q, Zhou D, Beasley A, Liu Y, et al
Identification of SLC3A2 as a Potential Therapeutic Target of Ferroptosis in Bladder Cancer.
Arch Esp Urol. 2026;79:36-48.
PubMed
Abstract available

MCKAY RR, Tipirneni A, Bangs R, Guercio BJ, et al
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.
Am Soc Clin Oncol Educ Book. 2026;46:e516902.
PubMed
Abstract available

GIRGIN R, Mungan NA
Turkish urologists' knowledge and attitudes on lifestyle advice for bladder cancer: a national survey.
Support Care Cancer. 2026;34:260.
PubMed
Abstract available

YAMADA S, Sato M, Osawa T, Harabayashi T, et al
Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.
Cancer Sci. 2026;117:739-748.
PubMed
Abstract available

NOGUEIRA CM, Machado C, Santos RB, Faustino AS, et al
Infiltrated penile papules as a cutaneous manifestation of disseminated BCGitis: A rare dermatologic presentation.
Int J STD AIDS. 2026;37:444-446.
PubMed
Abstract available

STARRETT JH, Allen EL, Neal M, Iyer S, et al
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
Mol Cancer Ther. 2026;25:408-415.
PubMed
Abstract available

SHUKLA A, Hiralal, Raj H, Surekha S, et al
Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in bladder cancer: Insight from a prospective tertiary care study.
Urologia. 2026 Mar 13:3915603261429445. doi: 10.1177/03915603261429445.
PubMed
Abstract available

TAN K, Quan X, Tan M, Han Z, et al
Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report.
Front Oncol. 2026;16:1734661.
PubMed
Abstract available

WANG X, Zhao J, Li Q, Chang J, et al
Disulfidptosis and androgenic cancers: from molecular mechanisms to clinical applications and future translational research.
Front Endocrinol (Lausanne). 2026;17:1783929.
PubMed
Abstract available

LI Z, Yu Y, Liu F, Wu Y, et al
Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
Sci Rep. 2026 Mar 13. doi: 10.1038/s41598-026-42815.
PubMed
Abstract available

HERMANN-VARADI M
[Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors].
Magy Onkol. 2026;70:85-87.
PubMed
Abstract available

PULUGOR GD, Galdi A, Varga L, Jorgo K, et al
[Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].
Magy Onkol. 2026;70:23-31.
PubMed
Abstract available

CERBONE L, Roviello G, Calabro F, Taha T, et al
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
Front Immunol. 2026;17:1667155.
PubMed
Abstract available

HAO Z, Zhu L, Ding J, Jin Q, et al
bp-VI-RADS combined with normalized apparent diffusion coefficient enhances diagnostic efficacy for muscle-invasive bladder cancer.
Quant Imaging Med Surg. 2026;16:244.
PubMed
Abstract available

LIU W, Xiao J, Zou J, He Z, et al
Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.
Asian J Urol. 2026;13:11-23.
PubMed
Abstract available

LIU S, Wang M, Wang W
[Analysis of urine biomarkers in urothelial carcinoma based on untargeted metabolomics].
Se Pu. 2026;44:329-337.
PubMed
Abstract available

MANCIN S, Ferrara G, Palomares SM, Matteucci S, et al
Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-Analysis.
Cancer Med. 2026;15:e71672.
PubMed
Abstract available

LODEWIJK I, Rubio C, Eriksson P, Reina IA, et al
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.
Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-42566.
PubMed

BOLENZ C, Heidenreich A
[From limited options to individualized strategies: advances in the treatment of bladder cancer].
Urologie. 2026;65:239-241.
PubMed

JIANG Y, Li J, Yang Z, Ma M, et al
Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
Cancer Immunol Immunother. 2026;75:103.
PubMed
Abstract available

MASON B, Eccleston A, Ayala-Nunes L, Hauber B, et al
Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
Patient. 2026 Mar 11. doi: 10.1007/s40271-026-00804.
PubMed
Abstract available

ITO K, Yamashita R, Kasai S, Sakura Y, et al
A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.
IJU Case Rep. 2026;9:e70155.
PubMed
Abstract available

FAN G, Luo X, Li K, Zhang Z, et al
Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
Asian J Pharm Sci. 2025;20:101095.
PubMed
Abstract available

LIANG S, Liu H, Su Q, Li X, et al
Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor.
Transl Androl Urol. 2026;15:46.
PubMed
Abstract available

LIU J, Tang X, Cui Y, Yang X, et al
Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.
Transl Androl Urol. 2026;15:60.
PubMed
Abstract available

WANG Q, Pei CS, Cao JY, Peng H, et al
Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
Cancer Manag Res. 2026;18:583762.
PubMed
Abstract available

WISHAHI M
Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.
World J Gastrointest Pharmacol Ther. 2026;17:115573.
PubMed
Abstract available

SU Y, Wu J, Deng Z, Luo Y, et al
In Vivo Target Drug Enrichment Based on Spatiotemporal Acoustic Node Modulation (STANM) for Bladder Cancer Treatment.
Adv Mater. 2026 Mar 10:e17740. doi: 10.1002/adma.202517740.
PubMed
Abstract available

GAO Y, Yang F, Yin L, Wang W, et al
A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in Bladder Cancer.
ACS Nano. 2026 Mar 10. doi: 10.1021/acsnano.5c21831.
PubMed
Abstract available

VAN CREIJ NCH, Tymoszuk P, Handle F, Seeber A, et al
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.
Clin Transl Med. 2026;16:e70638.
PubMed
Abstract available

QIN S, Luo H, Hong Y, Fu C, et al
Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
Abdom Radiol (NY). 2026 Mar 9. doi: 10.1007/s00261-026-05390.
PubMed
Abstract available

DONMEZ K, Yorulmaz EM, Candemir E, Ozcan S, et al
Unusual metastatic patterns of urologic malignancies: a case series and literature review.
Can J Urol. 2026;33:211-219.
PubMed
Abstract available

AKKAD A, Bruyere F, Bourgi A
Uretero-enteric strictures after cystectomy: revealing the modifiable risk factors.
Can J Urol. 2026;33:155-163.
PubMed
Abstract available

ZHAN M, Zhou Z, Zhang J, Wang X, et al
Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.
Can J Urol. 2026;33:35-49.
PubMed
Abstract available

NIE Q, Jiang M, Wan S, Xi M, et al
Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target.
PeerJ. 2026;14:e20917.
PubMed
Abstract available

LI Z, Wang G, Tan S, Wang Y, et al
Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with clinicopathological features.
Front Oncol. 2026;16:1757293.
PubMed
Abstract available

FENG R, Zhang J, Tao Y, Hou J, et al
Correction: Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
Front Oncol. 2026;16:1787982.
PubMed
Abstract available

HUANG Z, Cao X, Yan Y, Li H, et al
Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation.
Int J Med Sci. 2026;23:986-1001.
PubMed
Abstract available

ISTAMULOV M, Eriksson H, Abuhasanein S
Standardized care pathway reshaped the diagnostic and therapeutic landscape of urinary bladder cancer. A 15-year population-based study.
BJUI Compass. 2026;7:e70179.
PubMed
Abstract available

MENGYAN J, Jun Q, Wen L, Tingting P, et al
Research Progress on Financial Toxicity in Bladder Cancer Patients.
J Surg Oncol. 2026 Mar 8. doi: 10.1002/jso.70201.
PubMed
Abstract available

ZHANG Y, Liu L, Yang B, Wu Q, et al
Electron transfer-driven ultrathin nanozyme synergizes with nucleic acid amplification for bladder cancer screening.
Biosens Bioelectron. 2026;303:118580.
PubMed
Abstract available

SONG YS, Liu CK, Jiang WS, Liu J, et al
Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in bladder cancer by blocking Akt-SREBP1-SCD1 pathway.
Phytomedicine. 2026;154:158011.
PubMed
Abstract available

QIN Z, Zhou H, Hu Y, Xiong X, et al
Survival prediction for bladder cancer using multimodal data with quantum neural networks and transformer architectures.
Sci Rep. 2026 Mar 7. doi: 10.1038/s41598-026-42047.
PubMed
Abstract available

LIJNEN RAG, Ringia JB, Claps F, Vogel WV, et al
Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.
Eur Urol Oncol. 2026 Mar 6:S2588-9311(26)00046-5. doi: 10.1016/j.euo.2026.
PubMed
Abstract available

YAN H, Yin C, Xu F, Li R, et al
Unraveling the connection between PFOA and bladder cancer: A study integrating network toxicology, molecular docking, and experimental validation.
Toxicol Appl Pharmacol. 2026;511:117784.
PubMed
Abstract available

NUR BUDAYA T, Seputra KP, Susianti H, Aditya Hutama S, et al
Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection and Evaluation Method for Bladder Cancer.
Asian Pac J Cancer Prev. 2026;27:911-920.
PubMed
Abstract available

LI P, Li L, Li Z, Wang S, et al
Correction: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.
Cancer Cell Int. 2026;26:119.
PubMed

LI J, He Y, Wu S
Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following Repeat Transurethral Resection: A Meta-Analysis.
J Coll Physicians Surg Pak. 2026;36:87-94.
PubMed
Abstract available

GUO X, Zhu C, Yin Z
A positive SPTBN2-FLI1 feedback axis promotes bladder cancer via PI3K/AKT activation.
Cell Signal. 2026 Mar 4:112471. doi: 10.1016/j.cellsig.2026.112471.
PubMed
Abstract available

QI T, Yang W, Liu R, Deng D, et al
SWI/SNF-associated molecular subtypes reshape tumor microenvironmental features and inform precision therapeutic strategies in bladder cancer.
Front Cell Infect Microbiol. 2026;16:1774929.
PubMed
Abstract available

CAO JY, Peng H, Wang GY, Chang PA, et al
IGF2BP3 promotes the muscle invasion of bladder cancer via PPARgamma dysregulation.
Discov Oncol. 2026 Mar 5. doi: 10.1007/s12672-026-04648.
PubMed

KHAN A, Alanazi FJ, Ahmed S, Alzahrani AR, et al
Glycoprotein biomarkers for bladder cancer detection.
Clin Chim Acta. 2026;586:120938.
PubMed
Abstract available

TANGUY M, Armelle P, Sheik E, Nicolas I, et al
Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study.
Fr J Urol. 2026 Mar 3:103093. doi: 10.1016/j.fjurol.2026.103093.
PubMed
Abstract available

ZHANG M, Wang K, Li G, Bao X, et al
Light-activated targeted degradation of VHL drug for selective tumor killing: A novel strategy for precision therapy of bladder cancer.
Eur J Med Chem. 2026;309:118736.
PubMed
Abstract available

GAO X, Liu J, Deng D, Xiao J, et al
The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
Int Immunopharmacol. 2026;175:116443.
PubMed
Abstract available

AJALLI MM, Sansebli Y, Ekrami D, Alaeenejad F, et al
Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.
Clin Exp Med. 2026 Mar 5. doi: 10.1007/s10238-026-02098.
PubMed

TIAN X, Liu Y, Mi Z, Liang Y, et al
CALR/HIF-1alpha Positive Feedback Loop Drives CALR Upregulation to Promote EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.
Cancer Sci. 2026 Mar 5. doi: 10.1111/cas.70354.
PubMed
Abstract available

Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".
Dis Markers. 2026;2026:9804137.
PubMed
Abstract available

MALSHY K, Messing EM
Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.
Bladder Cancer. 2026;12:23523735261429862.
PubMed

HE J, Jiang Z, Peng S, Peng L, et al
Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer.
Mol Genet Genomics. 2026;301:50.
PubMed
Abstract available

MIYAMOTO T, Miyake M, Nishimura N, Oda Y, et al
Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
Cureus. 2026;18:e102672.
PubMed
Abstract available

HUANG J, Hu H, Sun M, Wu W, et al
A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification.
NPJ Digit Med. 2026 Mar 3. doi: 10.1038/s41746-026-02499.
PubMed
Abstract available

DOMANSKI P, Hanusz K, Zapala L, Shah P, et al
Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2026 Feb 11:102514. doi: 10.1016/j.clgc.2026.102514.
PubMed
Abstract available

MENA E, Lindenberg L, Heng S, Choyke PL, et al
Advances and challenges of PET imaging in bladder cancer-An update and future trends.
Semin Nucl Med. 2026 Mar 2:S0001-2998(26)00046.
PubMed
Abstract available

KUROBE M, Ogawa T, Satoh Y, Yamamoto M, et al
Near infrared ray-guided partial cystectomy using da Vinci Firefly((R)) technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor.
Investig Clin Urol. 2026;67:178-185.
PubMed
Abstract available

YOON SG, Park TY, Jin HJ, Noh TI, et al
Long-term oncologic outcomes of robot-assisted radical cystectomy: Prognostic indicators and complication profiles from a high-volume single-surgeon series.
Investig Clin Urol. 2026;67:148-161.
PubMed
Abstract available

CHOI SY, Yang YJ, Min KC, Lee YS, et al
Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials.
Investig Clin Urol. 2026;67:131-139.
PubMed
Abstract available

AKIN Y, Yorulmaz EM, Gorgel SN, Ozcan S, et al
Who is Next? Impact of Systemic Immune-Inflammation Index and De Ritis Ratio for Predicting 90-Day Survival after Salvage Cystectomy in Advanced Bladder Cancer.
Arch Esp Urol. 2026;79:66-72.
PubMed
Abstract available

SARI H, Celik S, Yorukoglu K, Celebi I, et al
Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
Arch Esp Urol. 2026;79:58-65.
PubMed
Abstract available

Strategy to Analyze Urine Tumor DNA Predicts Outcomes in Bladder Cancer.
Cancer Discov. 2026 Feb 11:OF1. doi: 10.1158/2159-8290.CD-RW2026.
PubMed

SIDAWAY P
Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.
Nat Rev Clin Oncol. 2026 Mar 2. doi: 10.1038/s41571-026-01139.
PubMed

BARLAK BSR, Iskender B
Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
Cancer Genomics Proteomics. 2026;23:300-321.
PubMed
Abstract available

NECCHI A, Maiorano BA, de Jong JJ, Proudfoot JA, et al
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Lancet Oncol. 2026 Feb 27:S1470-2045(26)00050.
PubMed
Abstract available

WONG R, Matulewicz RS, Talwar R, Goldstein AO, et al
Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.
JCO Oncol Pract. 2026 Mar 2:OP2500780. doi: 10.1200/OP-25-00780.
PubMed
Abstract available

SUPERDOCK M, Wobker SE, Carmicheal I, Kim WY, et al
Computational pathology in bladder cancer: A scoping review.
Bladder Cancer. 2026;12:23523735251413333.
PubMed
Abstract available

BLUMENFELD P, Levy D, Hillman Y, Feldman J, et al
Daily artificial intelligence-assisted adaptive small margin radiotherapy during trimodal therapy of muscle-invasive bladder cancer.
Front Oncol. 2026;16:1729810.
PubMed
Abstract available

IMAI K, Masuda N, Hazama T, Hosomi T, et al
Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
IJU Case Rep. 2026;9:e70157.
PubMed
Abstract available

MEEKS JJ
The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
J Clin Invest. 2026;136:e202079.
PubMed
Abstract available

MOINARD-BUTOT F, Barbe-Richaud JB, Baudry E, Pierard L, et al
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
Urol Oncol. 2026;44:111036.
PubMed
Abstract available

CUADRA JDP, Perez MA, Gonzalez-Peramato P, Sanz J, et al
PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era.
Pathol Res Pract. 2026;281:156372.
PubMed
Abstract available

THU PHUNG TA, Weng R, Black PC, Dyrskjot L, et al
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.
Eur Urol Oncol. 2026 Feb 27:S2588-9311(26)00057.
PubMed
Abstract available

PRIETO MATIENZO L, Fischer-Straub A, Perera M, Babst C, et al
Follicular lymphoma of the urachus.
BMJ Case Rep. 2026;19:e267211.
PubMed
Abstract available

BENCINA G, Ruiz RA, Bencina B
Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework.
J Cancer Policy. 2026;48:100728.
PubMed
Abstract available

HUANG J, Ojo A, Liaw B
Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.
Curr Oncol. 2026;33:103.
PubMed
Abstract available

BURTZ M, Boss MK, Leary D, Martin TW, et al
Radiation therapy as a treatment for urinary obstruction secondary to urothelial carcinoma in dogs.
J Vet Intern Med. 2026;40:aalaf093.
PubMed
Abstract available

SONG SH, Park JH, Lee S, Jeong SH, et al
Oncological outcomes of concurrent nephroureterectomy during radical cystectomy: A propensity score-matched analysis with multivariable adjustment from Korean multicenter database.
Surg Oncol. 2026;65:102362.
PubMed
Abstract available

GAISA NT, Reis H, Heidenreich A
[Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].
Urologie. 2026;65:278-287.
PubMed
Abstract available

WEI G, Fan ZH, Huang RZ, Wei Y, et al
Design, synthesis and antitumor activity evaluation of 1,4-naphthoquinone-benzene sulfonamide hybrids.
Future Med Chem. 2026;18:637-648.
PubMed
Abstract available

ZHANG Q, Hong Y, He C, Guo R, et al
Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma.
Biochim Biophys Acta Mol Basis Dis. 2026;1872:168182.
PubMed
Abstract available

KOHLER J, Rodler S, Andersson J, Juptner M, et al
[Innovative imaging techniques for urothelial carcinoma].
Urologie. 2026;65:242-249.
PubMed
Abstract available

KIMBALL J, Steele J, Vargas SO, Hirsch M, et al
BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung Transplantation in Childhood.
Pediatr Dev Pathol. 2026;29:128-135.
PubMed
Abstract available

NIEGISCH G, Zschabitz S, Eckstein M, Klumper N, et al
[From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma].
Urologie. 2026;65:271-277.
PubMed
Abstract available

ORDOBAZARI A, Nikfar R, Zhao X, Davaro E, et al
Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria.
Diagn Cytopathol. 2026;54:299-306.
PubMed
Abstract available

FARTIYAL JS, Rao M, Elhence PA, Nalwa A, et al
Comparison of Conventional Sediment Smears and Liquid-Based Cytology and Utility of Cell Block Preparation in Urinary Cytology.
Diagn Cytopathol. 2026;54:285-292.
PubMed
Abstract available

MAN X, Dong C, Dong A, Song X, et al
FDG PET/CT in Primary Mucosa-associated Lymphoid Tissue Lymphoma of the Bladder.
Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006295.
PubMed
Abstract available

FORTIER A, Mokadem S, Saadi A, Gillibert A, et al
Does ureteroileal anastomosis technique (Bricker versus Wallace) influence benign ureteroileal stricture occurrence on transileal diversion?
Fr J Urol. 2026;36:103078.
PubMed
Abstract available

SRETENOVIC M, Bumbasirevic U, Bojanic N, Durutovic O, et al
Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients with Bladder Carcinoma Treated by Radical Cystectomy.
Ann Surg Oncol. 2026;33:3743-3751.
PubMed
Abstract available

CHEN C, An M, Zheng H, Pang M, et al
B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.
Cancer Cell. 2026;44:551-566.
PubMed
Abstract available

COLLINS K, Gupta S, Cheng L
Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.
Hum Pathol. 2026;169:106018.
PubMed
Abstract available

WANG Y, Wu N, Zhang F, Zhang S, et al
The Comprehensive Complication Index for Assessing Short-Term Complications of Urothelial Carcinoma with Variant Histology: A Patient-Based Study.
Ann Surg Oncol. 2026;33:3688-3697.
PubMed
Abstract available

LONGONI M, Le QC, Falkenbach F, Marmiroli A, et al
The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.
Ann Surg Oncol. 2026;33:3680-3687.
PubMed
Abstract available

D'AGOSTINO E, Pirola M, Callegari V, Tonni E, et al
Future directions for antibody-drug conjugates in urothelial cancer.
Expert Rev Anticancer Ther. 2026;26:321-332.
PubMed
Abstract available

KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of gemcitabine-docetaxel in the management of NMIBC: a scoping review of current status and future directions.
Expert Rev Anticancer Ther. 2026;26:333-344.
PubMed
Abstract available

KEANE KG, Redfern A, Lim J, Hayne D, et al
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction.
Expert Rev Anticancer Ther. 2026;26:307-320.
PubMed
Abstract available

WOO S, Luk L, Muglia VF, Briganti A, et al
VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee.
Eur Radiol. 2026;36:1093-1104.
PubMed
Abstract available

RIZKALLA CN, Tretiakova M, Williamson SR, Akgul M, et al
Overlapping Morphologic and Immunophenotypic Features of Plasmacytoid Urothelial Carcinoma and Urothelial Carcinoma With Osteoclast-Like Giant Cells.
Int J Surg Pathol. 2026;34:309-314.
PubMed
Abstract available

SCHNEIDEWIND L, Kiss B, Arnold N, Kranz J, et al
[Gender-specific differences in outcome and survival in early cystectomy : Systematic review].
Urologie. 2026;65:300-307.
PubMed
Abstract available

TUCKER J, Sharma V, Johnson M, Hibbert R, et al
Safety and Diagnostic Yield of Percutaneous Urinary Bladder Tumor Biopsy.
Abdom Radiol (NY). 2026;51:1444-1449.
PubMed
Abstract available

DENG Z, Li M, Li J, Jung M, et al
Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.
J Racial Ethn Health Disparities. 2026;13:1555-1571.
PubMed
Abstract available

GONG Z, He Y, Mi X, Li C, et al
Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
Aging (Albany NY). 2023;15:9479-9498.
PubMed
Abstract available

XU C, Zou W, Wang Y, Liu X, et al
Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.
Crit Rev Oncol Hematol. 2023;191:104137.
PubMed
Abstract available

GIESE M, Butea-Bocu M, Huber J, Groeben C, et al
[Prehabilitation prior to radical cystectomy].
Urologie. 2023;62:1034-1040.
PubMed
Abstract available

OEY O, Tiong SS, Wong SL, Navadgi S, et al
Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report.
Folia Med (Plovdiv). 2023;65:693-698.
PubMed
Abstract available

MENDES WEFELNBERG M, Reimer N, Baumann FT
[Exercise therapy in prehabilitation : Current findings in urology].
Urologie. 2023;62:1011-1016.
PubMed
Abstract available

ANDO K, Kurashina R, Motoi N, Iizuka T, et al
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Biochem Biophys Res Commun. 2023;676:165-170.
PubMed
Abstract available

ZHANG J, Guo F, Zhu J, He Z, et al
Ultrasensitive Electrochemiluminescence Immunosensor for Bladder Marker Human Complement Factor H-Related Protein Detection.
Anal Chem. 2023;95:11440-11448.
PubMed
Abstract available

PERUZZI V, Torresan S, Cortiula F, Fanelli M, et al
Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical Reasoning: An Illustrative Case-based Discussion.
Curr Probl Diagn Radiol. 2023;52:478-481.
PubMed
Abstract available

LU S, Zhang X, Cai Z, Xi Z, et al
Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs in bladder urothelial carcinoma.
J Biochem Mol Toxicol. 2023;37:e23441.
PubMed
Abstract available

YAMASHITA S, Wada T, Deguchi R, Mashima N, et al
Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab.
Jpn J Clin Oncol. 2023;53:845-850.
PubMed
Abstract available

DOUMANIDIS P, Tsagkozis P
Surgical Management of Bone Metastases in Bladder Cancer: A Single-Center Retrospective Study.
Cancer Rep (Hoboken). 2026;9:e70524.
PubMed
Abstract available

SLUSARCZYK A, Moschini M, Krajewski W, Scilipoti P, et al
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Mar 20. doi: 10.1245/s10434-026-19476.
PubMed
Abstract available

DUQUESNE I, Epelbaum I, Prost D, Haberstich M, et al
Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective.
Eur Urol Oncol. 2026 Mar 19:S2588-9311(26)00065.
PubMed
Abstract available

XU X, Liang R, Zhao A, Zhang J, et al
Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer.
Adv Sci (Weinh). 2026 Mar 20:e74876. doi: 10.1002/advs.74876.
PubMed
Abstract available

WU Q, Zhou Y, Ou Z, Fu H, et al
Peroxisomal activity drives aggressive bladder cancer phenotypes and reveals erythorbic acid as a potential therapeutic modulator.
Front Oncol. 2026;16:1734437.
PubMed
Abstract available

ICHAS M, Allard L, Harper L, Yacoub M, et al
Urothelial Carcinoma of the Bladder Following BK Virus Infection in a Pediatric Kidney Transplant Recipient.
Pediatr Transplant. 2026;30:e70303.
PubMed
Abstract available

PORRECA A, Marino F, De Marchi D, Giampaoli M, et al
Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer?
Cancer Treat Res Commun. 2026;47:101181.
PubMed
Abstract available

WANG Y, Zhang A, Che H, Gao J, et al
Coenzyme Q10 exerts anti-cancer effects in bladder cancer by inducing ROS-mediated apoptosis and autophagy.
J Bioenerg Biomembr. 2026 Mar 19. doi: 10.1007/s10863-026-10093.
PubMed

HU Z, Jiang N, Xie B, Zhou J, et al
CircBARD1 suppresses tumor progression driven by H3K18 lactylation-CCNA2 axis in human bladder cancer.
Cell Oncol (Dordr). 2026;49:58.
PubMed

EVANGELISTA L, Guglielmo P
From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.
Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03731.
PubMed

GUGLIELMO P, Perrone E, Librando M, Aghaee A, et al
Novel radiopharmaceuticals for bladder cancer evaluation.
Q J Nucl Med Mol Imaging. 2026 Mar 19. doi: 10.23736/S1824-4785.26.03706.
PubMed
Abstract available

GERSHMAN B, Perez-Londono A, Almohtasib J, Kaul S, et al
Voiding Dysfunction Among Older Adults With Non-Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder.
Neurourol Urodyn. 2026 Mar 19. doi: 10.1002/nau.70269.
PubMed
Abstract available

YAO W, Shen W, Zhou H, Dai X, et al
Bioinspired IgM-Mimetic Polyvalent Aptamer-Albumin Nanoplatform for Targeted Intravesical Therapy of Bladder Cancer.
Small. 2026 Mar 19:e14393. doi: 10.1002/smll.202514393.
PubMed
Abstract available

LONG M, Peng Y, Gade S, Nicholson H, et al
Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based Approach.
AAPS J. 2026;28:74.
PubMed
Abstract available

WATANABE H, Takeuchi M, Higaki A, Kojima Y, et al
Histopathological Basis of Peritumoral Enhancement in Muscle-invasive Bladder Cancer.
Magn Reson Med Sci. 2026 Mar 19. doi: 10.2463/mrms.mp.2025-0211.
PubMed
Abstract available

CHENG H, Lu L, Gong Y, Liu S, et al
Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy.
Biochem Pharmacol. 2026 Mar 16:117905. doi: 10.1016/j.bcp.2026.117905.
PubMed
Abstract available

CANO-VELASCO J, Luis-Cardo A, Moreno-Cortes JC, Carrasco-Loras L, et al
Impact of Intravesical BCG Therapy on Quality of Life in Non-Muscle-Invasive Bladder Cancer: A Prospective Evaluation Using The FACT-Bl Questionnaire.
Actas Urol Esp (Engl Ed). 2026 Mar 16:501937. doi: 10.1016/j.acuroe.2026.501937.
PubMed
Abstract available

FELTES BENITEZ N, Counago F, Paredes-Rubio S, Peleteiro Higuero P, et al
Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study.
Actas Urol Esp (Engl Ed). 2026 Mar 16:501967. doi: 10.1016/j.acuroe.2026.501967.
PubMed
Abstract available

BAHAR P, Perez-Londono A, Kaul S, Efstathiou J, et al
Population-based outcomes of chemoradiation therapy for muscle-invasive bladder cancer in older adults.
J Geriatr Oncol. 2026;17:102939.
PubMed
Abstract available

VANEGAS CARDENAS SA, Cantor EJ, de Vries E
Incidence, mortality, and five-year survival of bladder cancer in six population-based cancer registries in Colombia, 2003-2018.
Cancer Epidemiol. 2026;102:103049.
PubMed
Abstract available

KITANO H, Watanabe E, Tadera K, Nakano Y, et al
Urine culture-guided antibiotic prophylaxis reduces febrile pyelonephritis after ureteral stent removal following radical cystectomy.
World J Urol. 2026;44:249.
PubMed
Abstract available

RIBEIRO CPS, Fernandes R, Lourenco LMO
Smart Macrocycles: Cyclodextrin-Porphyrin Photosensitizers for Photodynamic Therapy in Human Bladder Cancer Cells.
ACS Appl Bio Mater. 2026 Mar 18:XXX. doi: 10.1021/acsabm.6c00053.
PubMed
Abstract available

SUN L, Liu C, Yuan L
Evolving patterns of bladder cancer mortality in US adults: a two-decade analysis reveals persistent disparities despite overall progress (1999-2020).
Front Oncol. 2026;16:1713506.
PubMed
Abstract available

VARADI M, Magyar B, Szeles A, Korda S, et al
Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer.
Pathol Oncol Res. 2026;32:1612333.
PubMed
Abstract available

JIE J, Wang Q, Chen Z, Hu C, et al
Multi-omics analysis and preliminary experimental validation of acetyl tributyl citrate (ATBC) promoting bladder cancer progression via the AKR1B1/EMT axis.
Environ Pollut. 2026;397:127970.
PubMed
Abstract available

SAKATANI T, Tanaka S, Murakami K, Jinno C, et al
Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer.
Exp Mol Pathol. 2026;146:105039.
PubMed
Abstract available

LI J, Ballas L, Ghatalia P
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer.
Am Soc Clin Oncol Educ Book. 2026;46:e515984.
PubMed
Abstract available

TURAN S, Gezmis CT, Israfilov A, Aydin M, et al
Primary Mucinous Bladder Adenocarcinoma.
Prague Med Rep. 2026;127:44-47.
PubMed
Abstract available

ZHANG C, Cao S, Zeng G, Dong Y, et al
APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.
Sci Rep. 2026 Mar 15. doi: 10.1038/s41598-026-44653.
PubMed

HUANG L, Sun X, Song T, Liu Z, et al
Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer.
J Control Release. 2026;393:114808.
PubMed
Abstract available

DUNST J
[Cystectomy plus perioperative enfortumab vedotin/pembrolizumab in bladder cancer].
Strahlenther Onkol. 2026;202:448-450.
PubMed

ASSEL M, Vickers AJ
Letter: Incarcerated Patients Present With More Advanced Bladder Cancer Stage: A Statewide Analysis.
Urol Pract. 2026 Mar 16:101097UPJ0000000000000987.
PubMed

ALWABEL W, Almisfer A, Alsamaani I, Aljaafri B, et al
Intravesical therapy for bladder cancer causing disseminated tuberculosis and perforated viscus: a case report.
J Surg Case Rep. 2026;2026:rjag131.
PubMed
Abstract available

MAHDIPOUR S, Modarressi MH, Noruzinia M
Methylation and Expression Analysis of POU4F2, HOXA9, RBM46, and TSGA10 Genes in Bladder Cancer Using Methyl-Sensitive Restriction Enzyme PCR (MSRE-PCR).
Cancer Manag Res. 2026;18:557943.
PubMed
Abstract available

YU H, Lei Q, Yang W, Cao M, et al
FAM-related prognostic molecular subtype screening identified epithelial-derived MAOA-inhibiting bladder cancer.
Front Cell Dev Biol. 2026;14:1732999.
PubMed
Abstract available

HE J, Liu X, Li S, Xia Z, et al
A systematic characterization of amino acid metabolism-related genes reveals molecular subtypes and a prognostic signature in bladder cancer.
Front Oncol. 2026;16:1754912.
PubMed
Abstract available

MAHATI SG, Wu J, Walter FM, Zhou Y, et al
Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case-control study.
Lancet Prim Care. 2026;2:None.
PubMed
Abstract available

BOUNOUAR O, El Moudane A, Andrea E, Jdaini A, et al
Urothelial Bladder Cancer With Cardiac Metastasis: A Case Report.
Cureus. 2026;18:e103414.
PubMed
Abstract available

LEASK J, Ibrahim I, Wilson B, Hendry J, et al
The Role of Socioeconomic Status in Influencing Stage at Presentation and Overall Survival in Bladder Cancer: Experience From the West of Scotland.
Cureus. 2026;18:e103399.
PubMed
Abstract available

HU X, Miao J, Huang Y, Yang Y, et al
Urinary Diversion-Specific Morbidity After Radical Cystectomy: A Ten-Year Institutional Experience.
Cancer Med. 2026;15:e71684.
PubMed
Abstract available

ZHAO K, Zhou Z, Ma X, Xiao X, et al
Progress and challenges in CAR-T cell therapy for bladder cancer.
Crit Rev Oncol Hematol. 2026;222:105275.
PubMed
Abstract available

HJORT PB, Jensen JE, Jensen JB, Ernst A, et al
Study of bladder cancer detection in standard white light versus AI-supported endoscopy-01 (RAISE-01) - Development and validation of an AI-based support tool.
Int J Med Inform. 2026;213:106390.
PubMed
Abstract available

MARDELLI C, Bertail T, Tachibana I, Verhoest G, et al
Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence.
Urol Oncol. 2026 Mar 13:111047. doi: 10.1016/j.urolonc.2026.111047.
PubMed
Abstract available

ZHANG L, Chen C, Huang W, Dong L, et al
PIN1 suppresses bladder cancer progression by inducing cellular senescence and activating the interferon response pathway.
Cell Signal. 2026;143:112476.
PubMed
Abstract available

PARRAO D, Gallegos H, Ruz K, Lay R, et al
Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer.
Int J Mol Sci. 2026;27:2237.
PubMed
Abstract available

DOMIAN N, Smereczanska M, Mrugacz M, Mlynarczyk G, et al
Comparative Evaluation of HMG Family Proteins and miR-106a-5p in Low-Grade Non-Invasive and High-Grade Muscle-Invasive Papillary Urothelial Carcinoma.
Int J Mol Sci. 2026;27:2089.
PubMed
Abstract available

VENKATESH A, Rodriguez Rosales RD, Kanumuambidi JP, Ishiyama Y, et al
Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response.
Cancers (Basel). 2026;18:875.
PubMed
Abstract available

KIM T, Shin D, Ahn HK, Moon YJ, et al
Urine-Based cfDNA Ensemble Modeling for Early Detection of Bladder Cancer Using Whole-Genome Methylation Sequencing.
Cancers (Basel). 2026;18:767.
PubMed
Abstract available

MELGAREJO SEGURA MT, Herraez Marcos M, Cano Garcia MC, Zambudio Munuera A, et al
De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration.
J Clin Med. 2026;15:1939.
PubMed
Abstract available

TANG Y, Wang L, Liu H, Zhu Q, et al
Advances in intravesical therapy for non-muscle-invasive bladder cancer.
Crit Rev Oncol Hematol. 2026;222:105271.
PubMed
Abstract available

BAI J
Impact of physiological ability and surgical stress score on postoperative complications in patients undergoing surgery for non-muscle-invasive bladder cancer.
Medicine (Baltimore). 2026;105:e47699.
PubMed
Abstract available

SABER TANHA A, Sadeghi R, Ghorbani H, Soltani S, et al
Lymphatic mapping and sentinel lymph node biopsy in urinary bladder cancer: A SPECT/CT-based experience.
Ann Nucl Med. 2026 Mar 13. doi: 10.1007/s12149-026-02181.
PubMed
Abstract available

PARIKH M, McMahon P, Eng S, Boateng F, et al
Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan.
Clin Genitourin Cancer. 2026;24:102516.
PubMed
Abstract available

LIU Y, Tang A, Wang H
Toxicogenomic Characterization of Perfluorooctanoic Acid-Associated Bladder Carcinogenesis.
Cell Biol Toxicol. 2026;42:47.
PubMed
Abstract available

ASLANOVA M, Pereanu W, Lawrence A, Wang H, et al
Tumor-Informed Circulating Tumor DNA (ctDNA) in Locally Advanced and Metastatic Urothelial Carcinoma: A Retrospective Single-Center Cohort.
Clin Genitourin Cancer. 2026;24:102512.
PubMed
Abstract available

KOLAHI AZAR H, Beheshtizadeh N, Rezapour R, Pourlak T, et al
p16 positivity as a potent indicator of high-grade histology and its interplay with HER2/neu in urothelial bladder carcinoma.
Tissue Cell. 2026;100:103390.
PubMed
Abstract available

ZHU J, Ma X, Xie F, Wang Y, et al
TNM Stage-Stratified Comparison Between Urachal and Nonurachal Adenocarcinomas of the Bladder: A Single-Center Retrospective Cohort Study.
Clin Genitourin Cancer. 2026;24:102509.
PubMed
Abstract available

LOMBARDO KA, Yoshida T, Johnson E, Fitzgerald K, et al
Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.
Exp Mol Pathol. 2026;145:105032.
PubMed
Abstract available

PEARSON M, Engen PA, Green SJ, Emerson J, et al
Microbial profiling of urothelial carcinoma and benign bladder tissue from formalin-fixed specimens.
Urol Oncol. 2026;44:110997.
PubMed
Abstract available

WU DJ, Chan E
Histologic mimics of urothelial carcinoma.
Semin Diagn Pathol. 2026;43:150993.
PubMed
Abstract available

KOMORI M, Ogawa M, Yonezawa T, Momoi Y, et al
Significance of monocyte-to-lymphocyte ratio as a prognostic factor in canine urothelial carcinoma: a retrospective study.
J Vet Med Sci. 2026;88:485-491.
PubMed
Abstract available

BRACARDA S, Mammone G, Mosillo C, Sirgiovanni G, et al
Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting.
Urol Oncol. 2026;44:110986.
PubMed
Abstract available

BAS-CUTRINA F, Morales-Alvarado VJ, Gomis-Marti M, Jimenez-Serrano E, et al
Endoscopic vacuum therapy for leaky cavities: is it possible?
Rev Esp Enferm Dig. 2026;118:112-114.
PubMed
Abstract available

ERGUL RB, Kucukgergin C, Cincin ZB, Cakmakoglu B, et al
Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer.
Sci Rep. 2026 Mar 26. doi: 10.1038/s41598-026-36530.
PubMed

GONDA M, Kawai N, Ishikawa D, Aoki M, et al
Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.
Int J Hyperthermia. 2026;43:2645413.
PubMed
Abstract available

XUE Z, Qie Y, Liang S, Li R, et al
Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.
JCO Oncol Pract. 2026 Mar 26:OP2501242. doi: 10.1200/OP-25-01242.
PubMed
Abstract available

FRIESEN MC, Xie S, Locke SJ, Baris D, et al
Enhancing a job exposure matrix with subject-specific information to assess combined exposure to benzene, toluene, and xylene in a case-control study.
Ann Work Expo Health. 2026;70:wxag014.
PubMed
Abstract available

RUAN JL, Lee C, Sharma O, Lovgren N, et al
FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model.
Br J Radiol. 2026 Mar 26:tqag071. doi: 10.1093.
PubMed
Abstract available

QIAO S, Li Y, Gao Y, Li K, et al
Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis.
Anal Chem. 2026 Mar 26. doi: 10.1021/acs.analchem.6c00373.
PubMed
Abstract available

CHAN KH, Cen P, Shu T, Canfield S, et al
Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.
J Int Med Res. 2026;54:3000605261430450.
PubMed
Abstract available

LIEDBERG F, Holmberg L, Jarvholm B, Liv P, et al
[Why has bladder cancer incidence not decreased like in lung cancer?].
Lakartidningen. 2026;123:25097.
PubMed
Abstract available

VENHOMAA T, Nikulainen I, Bobjer J, Blackberg M, et al
Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study.
Scand J Urol. 2026;61:72-79.
PubMed
Abstract available

XU MC, Sandberg ML, Childs DD, Cengiz TB, et al
Synergy of PET and MR imaging in the local and regional staging of bladder cancer.
Ther Adv Urol. 2026;18:17562872261430967.
PubMed
Abstract available

XIAO Y, Zhang J, Jia Y, Song H, et al
Cigarette Smoking-Regulated PRKCE Is Involved in Bladder Cancer Susceptibility through cGMP/PKG-Dependent Glycolysis.
Environ Health (Wash). 2025;4:365-378.
PubMed
Abstract available

DE SOUZA RODRIGUES MR, da Silva IM, Leite Vacario BG, Oliveira Rocha LM, et al
Genetic variants in 8-oxoguanine DNA glycosylase 1 (OGG1) and X-ray repair cross-complementing protein 1 (XRCC1) and non-genetic factors are associated with bladder cancer susceptibility and prognosis in a Brazilian population.
J Toxicol Environ Health A. 2026 Mar 25:1-13. doi: 10.1080/15287394.2026.2647858
PubMed
Abstract available

KESSLER ER, Hoover K, Coats H, Fischer SM, et al
Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer.
Support Care Cancer. 2026;34:366.
PubMed
Abstract available

NIEGISCH G, Gakis G, Ohlmann CH, Knuchel-Clarke R, et al
[Perioperative therapy for muscle-invasive bladder cancer-current treatment concepts].
Urologie. 2026 Mar 25. doi: 10.1007/s00120-026-02810.
PubMed
Abstract available

TORNESELLO ML, Piccirillo MC, Tambaro R, Simeon V, et al
Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.
Front Immunol. 2026;17:1771897.
PubMed
Abstract available

LIU MY, Lin SY
[Caring for a Patient With Rare Urachal Carcinoma and Facilitating Family Medical Decision-Making: A Case Report].
Hu Li Za Zhi. 2026;73:e26213.
PubMed
Abstract available

YAN X, Tang X, Guo L, He Z, et al
Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.
Cancer Med. 2026;15:e71737.
PubMed
Abstract available

KOLANUKUDURU KP, Ben-David R, Hug B, Eraky A, et al
Therapeutic efficacy of Gemcitabine/Docetaxel maintenance in patients with non-muscle-invasive bladder cancer receiving initial Bacillus Calmette-Guerin induction.
Urol Oncol. 2026 Mar 23:111078. doi: 10.1016/j.urolonc.2026.111078.
PubMed
Abstract available

SUARTZ CV, de Carvalho PRS, Freitas RA, de Souza AM Neto, et al
The Perioperative Revolution in Muscle-Invasive Bladder Cancer - Progress, Caution, and the Latin American Perspective.
Int Braz J Urol. 2026;52:e20260158.
PubMed

MOLLICA V, Massari F, Fujita K, Giannatempo P, et al
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
Cancer Immunol Immunother. 2026;75:119.
PubMed
Abstract available

SALVAGGIO G, Comelli A, Albano D, Galia M, et al
Artificial intelligence and radiomics in bladder cancer MRI: a scoping review of applications, performance, and barriers to clinical translation.
Abdom Radiol (NY). 2026 Mar 24. doi: 10.1007/s00261-026-05457.
PubMed
Abstract available

ARTILES MEDINA A, Aumatell J, Gonzalez-Padilla DA, Pichler R, et al
The updated 2021 EAU risk groups for non-muscle-invasive bladder cancer: what have we learned four years after implementation?
Minerva Urol Nephrol. 2026 Mar 24. doi: 10.23736/S2724-6051.26.06915.
PubMed

PEYTON CC, Dhanda R, Burke T, Tsurutis V, et al
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.
Res Rep Urol. 2026;18:591097.
PubMed
Abstract available

AVILEZ ND, Tineo RN, Rodrigues JT, Ottaiano AD, et al
Comparison of [(18)F]FDG and [(18)F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study.
Mol Imaging Biol. 2026 Mar 23. doi: 10.1007/s11307-026-02085.
PubMed
Abstract available

KOCH J, Xu J, Bormann F, Coutinho Carneiro V, et al
The bladder cancer m(6)A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylation.
EMBO Rep. 2026 Mar 23. doi: 10.1038/s44319-026-00739.
PubMed
Abstract available

SINGH AK, Praharaj M, Lombardo KA, Yoshida T, et al
Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.
Nat Commun. 2026;17:2707.
PubMed

LEE NJ, Polverino F, Quarta L, Filzmayer M, et al
Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy.
Urol Oncol. 2026 Mar 22:111076. doi: 10.1016/j.urolonc.2026.111076.
PubMed
Abstract available

NGUYEN ME MD, Cepek J MD, PhD, FRCPC, Charlebois J MD FRCPC, Rosebush P MD, FRCPC, et al
Elevations in serum lithium levels postcystectomy and ileal conduit.
BMJ Case Rep. 2026;19:e267862.
PubMed
Abstract available

XU L, Zeng Z, Zou X, Zhu Z, et al
Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.
Discov Oncol. 2026 Mar 23. doi: 10.1007/s12672-026-04851.
PubMed
Abstract available

O'MAHONY CJ, Low E, Lynch OE, Daly K, et al
Investigation of non-visible haematuria in a tertiary urology service.
Ir Med J. 2026;119:41.
PubMed
Abstract available

ZHANG X, Wu X, Du J, Mei J, et al
Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms.
Int J Nanomedicine. 2026;21:575926.
PubMed
Abstract available

KLINGENBERG S, Lindgren MS, Jakobsen JK, Jensen JB, et al
DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2026 Mar 20:S2588-9311(26)00066.
PubMed
Abstract available

ULLAH A, Liu X, Zeng Y, Zhou C, et al
Red ginseng polysaccharide targets the PI3K/AKT/mTOR pathway to induce mitochondrial apoptosis in bladder cancer.
Int J Biol Macromol. 2026 Mar 19:151524. doi: 10.1016/j.ijbiomac.2026.151524.
PubMed
Abstract available

RAIZENNE BL, Koshkin VS, Zhu A, Ben-David R, et al
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2026;24:102524.
PubMed

KORONICA R, De Leonardis F, Servedio M, Novielli C, et al
Ifosfamide-Induced Encephalopathy in a Very Young Child With Rhabdomyosarcoma: Case Report and Literature Review.
J Pediatr Hematol Oncol. 2026;48:139-141.
PubMed
Abstract available

LU Z, Yang W, Hong Y, Qiao Y, et al
Delivery of Multifunctional Microspheres via Intravesical Instillation for Bladder Carcinoma: Therapeutic Potential and Mechanistic Insights.
Adv Healthc Mater. 2026;15:e04290.
PubMed
Abstract available

TOKUNAGA R, Yamauchi T, Den H, Omotaka S, et al
Epidemiology and treatment patterns of urachal remnants in adult patients with omphalitis: a nationwide claims-based study in Japan.
Surg Today. 2026;56:436-444.
PubMed
Abstract available

HASHIMOTO M, Fukiage K, Minami T, De Velasco MA, et al
Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.
Histol Histopathol. 2026;41:545-552.
PubMed
Abstract available

HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
Aligning bladder cancer research with patient needs: an update on research priorities.
BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
PubMed

SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
PubMed
Abstract available

BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
Is there still a role for ureteric frozen section analysis during radical cystectomy?
BJU Int. 2026;137:659-666.
PubMed
Abstract available

BRYAN RT, Patel K, Ward DG
The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
PubMed

FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
PubMed
Abstract available

DAY E, Bizzarri FP, Waine E, Martin R, et al
Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
BJU Int. 2026;137:708-715.
PubMed
Abstract available

PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
BJU Int. 2026;137:684-689.
PubMed
Abstract available

SLUSARCZYK A, Scilipoti P, Contieri R, Krajewski W, et al
Refining BCG-failure classifications in non-muscle-invasive bladder cancer.
BJU Int. 2026 Mar 19. doi: 10.1111/bju.70231.
PubMed
Abstract available

Correction to "Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer".
BJU Int. 2026 Mar 19. doi: 10.1111/bju.70248.
PubMed

SATHIANATHEN N, Perera M, Ischia J, Lawrentschuk N, et al
Use of MRI in the diagnosis of bladder cancer: a health economic analysis.
BJU Int. 2026 Mar 18. doi: 10.1111/bju.70243.
PubMed

ROESSLER N, Miszczyk M, Gontero P, Dematteis A, et al
Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.
BJU Int. 2026 Mar 16. doi: 10.1111/bju.70214.
PubMed
Abstract available

YE T, Tura B, Abbotts B, Zeegers MP, et al
Clinical outcomes of BCG-treated patients with high-risk non-muscle-invasive bladder cancer according to pre- and post-2021 European Association of Urology risk classifications.
BJU Int. 2026 Mar 23. doi: 10.1111/bju.70247.
PubMed

WU Z, Cao L, Zeng J, Feng W, et al
Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sample.
Cancer. 2026;132:e70373.
PubMed
Abstract available

GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
Cancer Res. 2023;83:3340-3353.
PubMed
Abstract available

GONZALEZ-PADILLA DA, Subiela JD, Guerrero-Ramos F, Pichler R, et al
Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.
Curr Opin Urol. 2026 Mar 4. doi: 10.1097/MOU.0000000000001373.
PubMed
Abstract available

CLARK PE
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
PubMed

NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
PubMed

LIU P, Chen J, Zhou J
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
PubMed

GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
PubMed
Abstract available

CONTIERI R, Lazzeri M, Perdona S, Hurle R, et al
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1
Eur Urol. 2026 Mar 20:S0302-2838(26)02038-5. doi: 10.1016/j.eururo.2026.
PubMed

KITAMURA H, Nishiyama H
Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdona, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Nega
Eur Urol. 2026 Mar 20:S0302-2838(26)02039-7. doi: 10.1016/j.eururo.2026.
PubMed

SANO T, Ohe C, Motoki Y, Nakamoto T, et al
Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
Int J Urol. 2026;33:e70392.
PubMed
Abstract available

GOTO Y
Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
Int J Urol. 2026;33:e70405.
PubMed

SHINOHARA M, Yamamoto H, Kawashima Y, Sekine Y, et al
Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Int J Urol. 2026;33:e70425.
PubMed
Abstract available

PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
Int Urol Nephrol. 2026;58:921-929.
PubMed
Abstract available

NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
Int Urol Nephrol. 2026;58:861-871.
PubMed
Abstract available

ZHENG Q, Liao E, Chen D, Shan G, et al
Bladder cancer organoids: bridging pathological features and drug response for precision oncology.
Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
PubMed
Abstract available

THAKKER PU, Refugia JM, Casals R, Able C, et al
Stent-free rates in cutaneous ureterostomy urinary diversion after radical cystectomy.
Int Urol Nephrol. 2023;55:2809-2814.
PubMed
Abstract available

SRIVASTAVA A, Trivedi S, Singh Y, Kumar U, et al
Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population.
Int Urol Nephrol. 2026 Mar 17. doi: 10.1007/s11255-026-05067.
PubMed
Abstract available

TANG C, Wang T, Luo H, Xue J, et al
Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study.
Int Urol Nephrol. 2026;58:1291-1306.
PubMed
Abstract available

GUO C, Wei J, Wang Y, Zhang L, et al
Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.
Int Urol Nephrol. 2026 Mar 25. doi: 10.1007/s11255-026-05110.
PubMed
Abstract available

KAMAT AM, Hensley PJ, Maiorano BA, Li R, et al
Bacillus Calmette-Guerin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naive Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
J Clin Oncol. 2026 Mar 2:JCO2502670. doi: 10.1200/JCO-25-02670.
PubMed

UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical
J Urol. 2026;215:441-449.
PubMed
Abstract available

BEN-DAVID R, Raizenne BL, Eraky A, Duquesne I, et al
Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy.
J Urol. 2026 Mar 17:101097JU0000000000005034. doi: 10.1097/JU.0000000000005034.
PubMed
Abstract available

PRASAD SM, Shishkov D, Mihaylov NV, Genov P, et al
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.
J Urol. 2026 Mar 25:101097JU0000000000005041. doi: 10.1097/JU.0000000000005041.
PubMed
Abstract available

HU H, Zhan X, Xiong Y, Yuan R, et al
Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
Oncogene. 2026 Mar 24. doi: 10.1038/s41388-026-03730.
PubMed
Abstract available

SMELSER WW
Editorial Commentary: "Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
Urology. 2026 Mar 17:S0090-4295(26)00177-9. doi: 10.1016/j.urology.2026.
PubMed

ZHANG L, Cao J, Gao Z, Han C, et al
Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
PubMed

GAO WB, Yu JJ
Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
PubMed

FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
Mumio and bladder cancer: unlocking its potential in 3D cell culture.
BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
PubMed

HUO X, Qi J, Zhu Y, Song H, et al
Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum

;